320 related articles for article (PubMed ID: 23453632)
21. Exocrinopathy resembling Sjögren's syndrome induced by a murine retrovirus.
Suzuki K; Makino M; Okada Y; Kinoshita J; Yui R; Kanazawa H; Asakura H; Fujiwara M; Mizuochi T; Komuro K
Lab Invest; 1993 Oct; 69(4):430-5. PubMed ID: 8231110
[TBL] [Abstract][Full Text] [Related]
22. Sjögren's syndrome in the NOD mouse model is an interleukin-4 time-dependent, antibody isotype-specific autoimmune disease.
Gao J; Killedar S; Cornelius JG; Nguyen C; Cha S; Peck AB
J Autoimmun; 2006 Mar; 26(2):90-103. PubMed ID: 16413168
[TBL] [Abstract][Full Text] [Related]
23. Immunotherapeutic targets in estrogen deficiency-dependent Sjögren's syndrome-related manifestations.
Arakaki R; Ishimaru N; Hayashi Y
Immunotherapy; 2010 May; 2(3):339-46. PubMed ID: 20635899
[TBL] [Abstract][Full Text] [Related]
24. Abnormal expression and function of Fas ligand of lacrimal glands and peripheral blood in Sjögren's syndrome patients with enlarged exocrine glands.
Tsubota K; Fujita H; Tadano K; Onoda N; Tsuzaka K; Takeuchi T
Clin Exp Immunol; 2002 Jul; 129(1):177-82. PubMed ID: 12100038
[TBL] [Abstract][Full Text] [Related]
25. The geoepidemiology of Sjögren's syndrome.
Mavragani CP; Moutsopoulos HM
Autoimmun Rev; 2010 Mar; 9(5):A305-10. PubMed ID: 19903539
[TBL] [Abstract][Full Text] [Related]
26. A novel NOD-derived murine model of primary Sjögren's syndrome.
Robinson CP; Yamachika S; Bounous DI; Brayer J; Jonsson R; Holmdahl R; Peck AB; Humphreys-Beher MG
Arthritis Rheum; 1998 Jan; 41(1):150-6. PubMed ID: 9433880
[TBL] [Abstract][Full Text] [Related]
27. Pro-inflammatory cytokines enhance ERAD and ATF6α pathway activity in salivary glands of Sjögren's syndrome patients.
Barrera MJ; Aguilera S; Castro I; Cortés J; Bahamondes V; Quest AFG; Molina C; González S; Hermoso M; Urzúa U; Leyton C; González MJ
J Autoimmun; 2016 Dec; 75():68-81. PubMed ID: 27461470
[TBL] [Abstract][Full Text] [Related]
28. The role of apoptosis in Sjögren's syndrome.
Bolstad AI; Jonsson R
Ann Med Interne (Paris); 1998 Feb; 149(1):25-9. PubMed ID: 11490513
[TBL] [Abstract][Full Text] [Related]
29. Development of Sjogren's syndrome in nonobese diabetic-derived autoimmune-prone C57BL/6.NOD-Aec1Aec2 mice is dependent on complement component-3.
Nguyen CQ; Kim H; Cornelius JG; Peck AB
J Immunol; 2007 Aug; 179(4):2318-29. PubMed ID: 17675493
[TBL] [Abstract][Full Text] [Related]
30. Effective treatment of a mouse model of Sjögren's syndrome with eyedrop administration of anti-CD4 monoclonal antibody.
Hayashi Y; Ishimaru N; Arakaki R; Tsukumo S; Fukui H; Kishihara K; Shiota H; Yasutomo K; Hayashi Y
Arthritis Rheum; 2004 Sep; 50(9):2903-10. PubMed ID: 15457459
[TBL] [Abstract][Full Text] [Related]
31. IL-4-STAT6 signal transduction-dependent induction of the clinical phase of Sjögren's syndrome-like disease of the nonobese diabetic mouse.
Nguyen CQ; Gao JH; Kim H; Saban DR; Cornelius JG; Peck AB
J Immunol; 2007 Jul; 179(1):382-90. PubMed ID: 17579059
[TBL] [Abstract][Full Text] [Related]
32. Common T cell receptor clonotype in lacrimal glands and labial salivary glands from patients with Sjögren's syndrome.
Matsumoto I; Tsubota K; Satake Y; Kita Y; Matsumura R; Murata H; Namekawa T; Nishioka K; Iwamoto I; Saitoh Y; Sumida T
J Clin Invest; 1996 Apr; 97(8):1969-77. PubMed ID: 8621782
[TBL] [Abstract][Full Text] [Related]
33. Th1 versus Th2 immune responses in autoimmune lacrimal gland disease in MRL/Mp mice.
Jabs DA; Lee B; Whittum-Hudson JA; Prendergast RA
Invest Ophthalmol Vis Sci; 2000 Mar; 41(3):826-31. PubMed ID: 10711700
[TBL] [Abstract][Full Text] [Related]
34. Lymphocytic infiltration and enlargement of the lacrimal glands: a new subtype of primary Sjögren's syndrome?
Parkin B; Chew JB; White VA; Garcia-Briones G; Chhanabhai M; Rootman J
Ophthalmology; 2005 Nov; 112(11):2040-7. PubMed ID: 16168486
[TBL] [Abstract][Full Text] [Related]
35. Salivary gland changes in the NOD mouse model for Sjögren's syndrome: is there a non-immune genetic trigger?
Humphreys-Beher MG; Yamachika S; Yamamoto H; Maeda N; Nakagawa Y; Peck AB; Robinson CP
Eur J Morphol; 1998 Aug; 36 Suppl():247-51. PubMed ID: 9825931
[TBL] [Abstract][Full Text] [Related]
36. Epigallocatechin-3-gallate modulates antioxidant and DNA repair-related proteins in exocrine glands of a primary Sjogren's syndrome mouse model prior to disease onset.
Ohno S; Yu H; Dickinson D; Chu TC; Ogbureke K; Derossi S; Yamamoto T; Hsu S
Autoimmunity; 2012 Nov; 45(7):540-6. PubMed ID: 22849293
[TBL] [Abstract][Full Text] [Related]
37. Apoptosis and Sjögren syndrome.
Manganelli P; Fietta P
Semin Arthritis Rheum; 2003 Aug; 33(1):49-65. PubMed ID: 12920696
[TBL] [Abstract][Full Text] [Related]
38. IL-14 alpha, the nexus for primary Sjögren's disease in mice and humans.
Shen L; Suresh L; Li H; Zhang C; Kumar V; Pankewycz O; Ambrus JL
Clin Immunol; 2009 Mar; 130(3):304-12. PubMed ID: 19038581
[TBL] [Abstract][Full Text] [Related]
39. Act1 is a negative regulator in T and B cells via direct inhibition of STAT3.
Zhang CJ; Wang C; Jiang M; Gu C; Xiao J; Chen X; Martin BN; Tang F; Yamamoto E; Xian Y; Wang H; Li F; Sartor RB; Smith H; Husni ME; Shi FD; Gao J; Carman J; Dongre A; McKarns SC; Coppieters K; Jørgensen TN; Leonard WJ; Li X
Nat Commun; 2018 Jul; 9(1):2745. PubMed ID: 30013031
[TBL] [Abstract][Full Text] [Related]
40. Central role for marginal zone B cells in an animal model of Sjogren's syndrome.
Shen L; Gao C; Suresh L; Xian Z; Song N; Chaves LD; Yu M; Ambrus JL
Clin Immunol; 2016 Jul; 168():30-36. PubMed ID: 27140729
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
